Abstract 41P
Background
Most female carriers of germline BRCA1 mutation develop breast and/or ovarian cancer. However, the penetrance of BRCA1 pathogenic variants does not reach 100%, and the age at onset for BRCA1-associated breast cancer (BC) varies widely. This study aimed to evaluate whether the age-related likelihood of developing BC in BRCA1 mutation carriers is influenced by inherited variations in the host immune system.
Methods
Next-generation sequencing was utilized for genotyping of HLA class I and II genes (HLA-A, HLA-B, HLA-C, HLA-DPB1, HLA-DQB1, and HLA-DRB1/3/4/5) in patients with BRCA1-associated BC with early (<39 years, n = 215) and late (>57 years, n=108) age at onset. Age thresholds corresponding to the youngest and oldest quartiles of women were determined by analyzing the age distribution in 771 consecutive female BC patients carrying BRCA1 pathogenic variants.
Results
HLA-DQB1*06:03P prevalence was higher in the late-onset group due to the excess of allele carriers [25/108 (23.1%) vs. 22/215 (10.2%); adjusted OR 2.96 (95% CI 1.58 - 5.56), p < 0.001] and homozygous genotypes [3/108 (2.8%) vs. 0/215 (0%); OR 14.3 (95% CI 0.73 - 279.27), p = 0.08]. For all HLA-I loci, there was a trend toward an increase in the number of homozygous genotypes in the early-onset group. For the HLA-A locus this prevalence was significant [14.4% vs. 6.5%, p = 0.037; OR 2.4 (95% CI 1.03 - 5.72), p = 0.042]. The frequencies of HLA-DPB1, HLA-DQB1, and HLA-DRB3/4/5 homozygous genotypes did not differ between young-onset and late-onset BC patients. The maximum degree of homozygosity detected in this study was 6 out of 7 HLA class I/II loci; all six female carriers of these genotypes were diagnosed with BC before the age of 39 years [OR = 6.97 (95% CI 0.39 - 125.01), p = 0.187].
Conclusions
HLA-DQB1*06:03P is significantly overrepresented in late-onset versus young-onset BRCA1 heterozygous BC patients suggesting that this allele has a protective role. A reduced diversity of HLA class I alleles may contribute to the early manifestation of BC in BRCA1 mutation carriers.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation grant #22-15-00278.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
30P - Role of microRNA and CDKN2A/p16INK4a expression in the prognostication of oral squamous cell carcinoma
Presenter: Olha Burtyn
Session: Cocktail & Poster Display session
Resources:
Abstract
31P - Identification of proteins associated with mRNA processing and maturation by quantitative proteomic analysis in Indian cervical cancer patients
Presenter: Amrita Mukherjee
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Expression of STAT3 and hypoxia markers in repeatedly resected glioma patients
Presenter: Katerina Dvorakova
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Unraveling the mechanisms of cisplatin resistance in bladder organoid by single cell RNA sequencing
Presenter: Tingting Xie
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - Functional diagnostics and ex-vivo screening of erlotinib and nintedanib in non-small cell lung carcinoma: Implications for multidrug resistance and personalized therapy
Presenter: Jelena Dinić
Session: Cocktail & Poster Display session
Resources:
Abstract
35P - Enhancing efficacy of the MEK inhibitor trametinib in KRAS-mutated colorectal cancer cells
Presenter: Lee Ellis
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Comparison of pelitinib, tepotinib or docetaxel efficacy according to the copy number or gene alteration status of EGFR, MET, HRAS, KRAS and NRAS genes
Presenter: Dae Young Zang
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - NET-mediated radio-resistance in early-stage non-small cell lung cancer
Presenter: Malcolm Ryan
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - The use of antibiotics or proton pump inhibitors and the response to intravesical Bacillus Calmette Guérin therapy in non-muscle-invasive bladder cancer
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - YAP1 promotes sorafenib resistance by activation of TGFβ signaling pathway
Presenter: Chit Lai Chee
Session: Cocktail & Poster Display session
Resources:
Abstract